FDA Moves Ulixacaltamide Forward As Praxis Valuation Gap Draws Focus [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
The U.S. FDA has accepted Praxis Precision Medicines' New Drug Application for ulixacaltamide to treat essential tremor. The agency has also granted ulixacaltamide Breakthrough Therapy Designation. The NDA is supported by late stage clinical trial data in patients with essential tremor. Praxis Precision Medicines, listed as NasdaqGS:PRAX, focuses on treatments for central nervous system disorders, including movement disorders such as essential tremor. This latest FDA step places ulixacaltamide in a more formal review path and highlights the role of neurology focused drug developers in efforts to address conditions that affect daily function for many patients. For investors following NasdaqGS:PRAX, the NDA acceptance and Breakthrough Therapy Designation outline the next phase of regulatory milestones to watch. Attention now turns to the FDA review process, future regulatory interactions, and Praxis Precision Medicines' plans to prepare for a potential commercial launch if ulix
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines (PRAX): One of the Best Upside Stocks [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.MarketBeat
- Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.MarketBeat
- Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential TremorGlobeNewswire
- Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026GlobeNewswire
PRAX
Earnings
- 2/19/26 - Miss
PRAX
Sec Filings
- 4/14/26 - Form 8-K
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- PRAX's page on the SEC website